Japanese drugmaker Shionogi plans to increase production capacity for its coronavirus vaccine candidate, aiming to turn out enough vaccines for 30 million people per year by the end of 2021, as competition intensifies to develop COVID-19 treatments, Nikkei has learned.
Drugmakers from Japan, the U.S. and Europe have announced a more than $1 billion fund to invest in startups developing treatments for antibiotic-resistant infections.
Japanese, for decades famous for wearing masks either to filter out springtime pollen or to keep cold and flu season at bay, are now demanding the things in ever greater variations as they extend their habit into a new season, summer.
A cancer treatment that uses light to destroy tumors is under consideration for accelerated Japanese approval, a U.S. biotechnology affiliate of e-commerce giant Rakuten announced Monday, moving a step closer to the first-ever use of this type of therapy.
Omron has begun global sales of automated carrier robots fitted with ultraviolet lights or disinfectant sprayers that can sanitize hospitals and schools to prevent coronavirus infections, the Japanese company said Friday.
The head of Fast Retailing has pledged a total of 10 billion yen ($93 million) to Kyoto University to fund research into treatments for the new coronavirus and other communicable diseases.
Japan's Rohto Pharmaceutical said Tuesday it plans to launch clinical trials in August for a stem cell-based treatment for patients suffering severe symptoms induced by the novel coronavirus.
Japanese pharmaceutical company Shionogi will sign a licensing agreement this month aimed at mass-producing a proposed coronavirus test that provides faster results without requiring special equipment or technicians.
A team led by Japanese biotech venture AnGes will ready production capacity for 1 million doses of coronavirus vaccines by March, a fivefold increase from the original plan, in order to ensure swift access to the domestic population.
An app to help people stop smoking received government approval Friday, becoming the first prescription digital therapeutic in Japan and heralding an emerging field of treatments developed at lower cost.